Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31440674 | 1.00 | MAPT (0.57) | MAPTMAPK1POLBL3MBTL1OPRK1 | |
| SCHEMBL11377331 | 0.86 | MAPK1 (0.59) | MAPTMAPK1POLBL3MBTL1OPRK1 | |
| SCHEMBL26793959 | 0.85 | KMT2A (0.53) | MAPTMAPK1POLBKDM4ELMNA | |
| SCHEMBL29907140 | 0.85 | KMT2A (0.53) | MAPTMAPK1POLBKDM4ELMNA | |
| SCHEMBL18038271 | 0.84 | MAPK1 (0.57) | MAPTMAPK1POLBL3MBTL1OPRK1 | |
| SCHEMBL25319432 | 0.84 | MAPT (0.54) | MAPTMAPK1POLBL3MBTL1OPRK1 | |
| SCHEMBL5248286 | 0.83 | MAPK1 (0.56) | MAPTMAPK1POLBL3MBTL1OPRK1 | |
| SCHEMBL13285512 | 0.83 | MAPK1 (0.56) | MAPTMAPK1POLBL3MBTL1OPRK1 | |
| SCHEMBL70813 | 0.83 | MAPT (0.63) | MAPTMAPK1POLBL3MBTL1OPRK1 | |
| SCHEMBL72187 | 0.83 | MAPT (0.56) | MAPTMAPK1POLBL3MBTL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384780-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-120081844-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-118804916-B | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2025-04-01 | — | — | CN | disclosed |
| EP-4466269-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240368162-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118804916-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-11939329-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-11-16 | — | — | US | disclosed |
| CN-116514807-A | Naphthyridones derivative and preparation method thereof | 上海翰森生物医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20230234952-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234952-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2023141290-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-8129537-B2 | Compounds as PDE IV and TNF inhibitors | RHONE-POULENC RORER LIMITED (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20110158989-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-0741707-B1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE POULENC RORER LTD (GB) | 1998-04-01 | — | — | EP | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384780-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | MAPT 3390/4885MAPK1 2670/4885POLB 55/4885 |
| US-11939329-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | MAPT 3390/4885MAPK1 2670/4885POLB 55/4885 |
| US-20230234952-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | MAPT 3390/4885MAPK1 2670/4885POLB 55/4885 |
| US-20110158989-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | PARP1, PARP3, PARP2 | MAPT 1730/4885MAPK1 3234/4885POLB 34/4885 |
| US-20240368162-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | MAPT 3390/4885MAPK1 2670/4885POLB 55/4885 |
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | CYP3A7, UGT2B7, SFPQ | MAPT 843/4885MAPK1 2026/4885POLB 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.